Could zapping a different brain region tame epilepsy?
NCT ID NCT04692701
First seen Feb 12, 2026 · Last updated Jun 19, 2026 · Updated 19 times
Summary
This pilot study tests deep brain stimulation (DBS) of the medial pulvinar, a new target in the brain, for people with drug-resistant epilepsy who have not improved with other treatments. Twelve adults aged 18 to 60 will receive the stimulation and track their seizures for 12 months. The goal is to see if this approach can reduce seizure frequency and improve quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Neurologie
Nice, France, 13385, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
deep brain stimulation device targeting the medial pulvinar
What this could lead to
If successful, this could offer a new treatment option for people with drug-resistant epilepsy who have not responded to other therapies.
What could go wrong
This is a very small pilot study with only 12 participants, so results may not apply widely. The approach is still experimental and may not reduce seizures significantly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.